DDrare: Database of Drug Development for Rare Diseases

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-[N-metil-11C1-PK11195(PK); 18F-AV-1451; 18F-AV-45; 18F-FDG; 18F-RO6958948; AL; AL001; AMIODARONE; Amantadine; Amiodarone; Amyvid; BIIB092; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: ECOCAPTURE; Behavioral: ICM_APATHY_TASKS; C-11 PiB; Carbonate; Chloride; Citalopram; Davunetide; Davunetide (AL-108, NAP); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Donepezil; EVP-0334; F 18 T807; F-18; F-18 FDG; FRM-0334; Ferulic acid; Florbetapir (18F); Florbetapir 18F; Florbetapir 18F Injection; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Galantamine; Galantamine hydrobromide; Histone Deacetylase Inhibitor; Intranasal oxytocin; LMTM; LMTM/TRx0237; Leucine; Leuco-methylthioninium bis(hydromethanesulfonate); Lithium Carbonate; Lithium carbonate; MTC TRx0014-001 capsules; Memantine; Memantine hydrochloride; Metformin; Methylprednisolone; Methylthioninium; Methylthioninium chloride; N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); Neurohormonal mechanisms; Novolin-R insulin; Other: 13C6 Leucine; Other: MRI; Oxytocin; PEA-LUT; PR006; Phenothiazine; Pittsburgh Compound B; Pittsburgh Compound B (C-11 PiB); Prednisone; Procedure: Brain PET scan; Saline Nasal Mist; Sirolimus; Syntocinon; T807; TRx0237; Tau (18-F-AV-1451); Tolcapone; Vizamyl; Vizamyl (flutemetamol(F-18)); [18F]PI-2620

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00594737 (ClinicalTrials.gov)	October 2007	7/1/2008	Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia	An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia	Frontotemporal Dementia	Drug: memantine hydrochloride	Tiffany Chow, MD	H. Lundbeck A/S	Completed	40 Years	80 Years	Both	17	Phase 3	Canada
2	NCT00545974 (ClinicalTrials.gov)	October 2007	16/10/2007	Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia	A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia	Frontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic Dementia	Drug: memantine;Drug: Placebo pill	University of California, San Francisco	Forest Laboratories	Completed	40 Years	80 Years	All	81	Phase 4	United States
3	NCT00200538 (ClinicalTrials.gov)	September 2005	12/9/2005	Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients	Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients	Dementia	Drug: memantine	Nantes University Hospital	NULL	Completed	45 Years	75 Years	Both	52	Phase 2	France
4	NCT00187525 (ClinicalTrials.gov)	May 2004	13/9/2005	A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration		Frontotemporal Lobar Degeneration	Drug: Memantine	University of California, San Francisco	Forest Laboratories	Completed	40 Years	80 Years	Both		Phase 4	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00594737
(ClinicalTrials.gov)

October 2007

7/1/2008

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia

Frontotemporal Dementia

Drug: memantine hydrochloride

Tiffany Chow, MD

H. Lundbeck A/S

Completed

40 Years

80 Years

Both

Phase 3

Canada

NCT00545974
(ClinicalTrials.gov)

October 2007

16/10/2007

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

Frontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic Dementia

Drug: memantine;Drug: Placebo pill

University of California, San Francisco

Forest Laboratories

Completed

40 Years

80 Years

All

Phase 4

United States

NCT00200538
(ClinicalTrials.gov)

September 2005

12/9/2005

Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients

Dementia

Drug: memantine

Nantes University Hospital

NULL

Completed

45 Years

75 Years

Both

Phase 2

France

NCT00187525
(ClinicalTrials.gov)

May 2004

13/9/2005

A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

Frontotemporal Lobar Degeneration

Drug: Memantine

University of California, San Francisco

Forest Laboratories

Completed

40 Years

80 Years

Both

Phase 4

NULL